By Aaron Kesel
Volansi has partnered with Big Pharma Merck to launch a test program in rural North Carolina to examine their ability to deliver temperature-controlled vaccines from a central production facility to determine how far they can send them, Cheddar reported.
“Once vaccines are developed and are out there, distribution will be a key challenge,” CEO Hannan Parvizian told Cheddar. “We truly believe that autonomous aerial deliveries will enable access to all areas, both in high-infrastructure countries like here in the U.S. and also in other low-infrastructure countries in emerging markets like Africa and other places in the world.”
The drone is limited at sending packages that weigh 10-pounds, but the company says it can cover at least 50 miles in just a single run.
It has a 10-pound payload capacity and can cover a 50-mile radius on a single trip,” Parvizian said. “That allows us to carry not only a significant amount of payload but also the cargo box that is required to maintain the temperature of the payload throughout the mission.”
“That’s how we will be ramping up, starting out with more rural areas and eventually moving into much more densely populated areas,” Parvizian said.
Parvizian added that the drones are able to deliver around 80 percent of all drugs and medical supplies, including blood donations.
There are probably some specialty items that are heavier or require much more care or not compatible with this type of delivery, but right now we’re not seeing any sort of big limitations on the types of payloads we can transport,” he said.
Parvizian further said Volansi differs from its competitors in that all drones use vertical take-off and landing as opposed to a catapult launcher.
“That means we don’t require any sort of ground infrastructure for launch and recovery of our vehicles,” he said.
Pay no attention to automation taking yet another job from you humans. At this point it’s beating a dead horse, but Activist Post has warned you how automation would increase due to the ongoing pandemic.
A recent report by A3,